A comprehensive review of pharmaceutical CBD for epilepsy synthesized data from four pivotal RCTs showing significant seizure reduction in Dravet and Lennox-Gastaut syndromes, with notable drug interactions.
Neurologists, epileptologists, pharmacists managing anti-epileptic drug interactions, and families of patients with severe epilepsy.
4 RCTs: both 10 and 20 mg/kg/day CBD significantly reduced seizures
What the researchers found
Pharmaceutical CBD (Epidiolex) was approved based on four pivotal RCTs enrolling 154 Dravet and 396 Lennox-Gastaut syndrome patients. Both 10 and 20 mg/kg/day doses met primary endpoints for seizure reduction. Key adverse effects included somnolence, decreased appetite, diarrhea, and liver enzyme elevations (mainly with concomitant valproate). The CBD-clobazam interaction via CYP2C19 likely contributes to both efficacy and side effects.
Why it matters
This review provides the most complete picture of pharmaceutical CBD for epilepsy in one place, from molecular mechanisms through clinical trial results, helping clinicians understand both the benefits and the complexities.
The numbers in context
4 pivotal RCTs; 154 DS + 396 LGS patients; CBD 10-20 mg/kg/day; oral bioavailability 6%; metabolized by CYP3A4 and CYP2C19; liver enzyme elevations mainly with valproate co-administration.
How the study worked
Comprehensive narrative review covering CBD pharmacology, mechanisms of action, pharmacokinetics, drug interactions, and pivotal clinical trial data for epilepsy indications.
What this study cannot tell us
Narrative review format; pivotal trials were industry-sponsored; long-term data beyond trial periods are limited; results apply to pharmaceutical-grade CBD (Epidiolex) and may not generalize to consumer products.
How to read the evidence
Strong: synthesizes data from four pivotal double-blind RCTs that led to regulatory approval.
When this study was published
Published 2020.
The bigger picture
CBD represents a genuine pharmaceutical success story: from folk remedy to rigorous clinical trials to regulatory approval. Understanding its drug interactions is essential because most epilepsy patients take multiple medications.
Questions still open
- Will CBD prove effective for other epilepsy syndromes beyond DS and LGS? Can the clobazam interaction be managed to optimize both efficacy and tolerability?
Common questions
Which epilepsy syndromes does CBD treat?
What are the main drug interactions to watch for?
Read the original research
Cannabinoids in the Treatment of Epilepsy: Current Status and Future Prospects.
Neuropsychiatric disease and treatment, 16, 381-396
Citation
Morano, Alessandra; Fanella, Martina; Albini, Mariarita; Cifelli, Pierangelo; Palma, Eleonora; Giallonardo, Anna Teresa; Di Bonaventura, Carlo. (2020). Cannabinoids in the Treatment of Epilepsy: Current Status and Future Prospects.. Neuropsychiatric disease and treatment, 16, 381-396. https://doi.org/10.2147/NDT.S203782
Explore the wider topic
- CBD Oil Quality Guide: How to Avoid Snake Oil
- Anxiety After Quitting Weed: When to Consider Medication
- Cannabis for Chemotherapy Nausea: What the Evidence Actually Shows
- Cannabis for Chronic Pain: What the Research Actually Supports
- Cannabis and Epilepsy: The Epidiolex Story and What It Means
- Does CBD Actually Work for Anxiety? What the Evidence Shows
- Does CBD Help with Weed Withdrawal? What Studies Show
- CBD vs THC: The Differences That Actually Matter
- The Proven Medical Benefits of Cannabis: What Research Supports
- Quitting Weed Before Surgery
- Weed and Medications: What Changes When You Quit
- Quitting Weed During Pregnancy: What You Need to Know
- Quitting Weed While Pregnant: What You Need to Know
- Cannabis and Older Adults: Risks Seniors Should Know
- Cannabis and Breastfeeding: THC in Breast Milk